Nasal Sprays: Clinical Trials

60 trials of Nasal Sprays, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 8 unknown, 2 terminated, 1 withdrawn. 17 Phase 2, 15 Phase 3, 11 Phase 1, 9 Phase 4, 7 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 217Completed 15, Unknown 2
Phase 315Completed 12, Terminated 1, Unknown 1, Withdrawn 1
Phase 111Completed 9, Terminated 1, Unknown 1
Phase 49Completed 8, Unknown 1
Not applicable7Completed 7

Follow Nasal Sprays: new trials by email Literature Review of Nasal Sprays trials Research Report on Nasal Sprays

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP
Dexmedetomidine Injection (nasal spray) + Propofol Injection + Sufentanil Injection, Normal Saline (nasal spray) + Dexmedetomidine Injection (intravenous) + Propofol Injection + Sufentanil Injection, Regular sedation protocol - Dexmedetomidine Induced Sedation, Nasal Administration
Not applicableCompletedShiyou Wei1802025-10-022025-11-28
Feasibility, Acceptability, and Safety of a Drug-Free Nasal Spray in Frontline Healthcare Workers
Nasal Spray - Healthy Adults
Not applicableCompletedAkita Biosciences, Inc.1272025-02-262026-10-22
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops - COVID19, Sars-Cov-2
Phase 1CompletedRokote Laboratories Finland Oy402025-01-212025-12-08
Azelastine Allergen Chamber - Onset of Action Study
Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray - Seasonal Allergic Rhinitis
Phase 2CompletedMEDA Pharma GmbH & Co. KG842023-10-302024-03-20
Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.
Azelastine + Mometazone, nasal spray, Momat Rhino Advance - Seasonal Allergic Rhinitis
Phase 3CompletedSandoz4722023-02-132023-08-04
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease
Varenicline Tartrate Nasal Spray - Dry Eye Disease
Phase 1CompletedCorxel Pharmaceuticals92022-12-072023-05-01
Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children
Mometasone Furoate 50mcg Nasal Spray, Sodium Chloride 0.9 % Nasal Spray - Sleep Disorder; Breathing-Related, Snoring
Phase 4CompletedMurdoch Childrens Research Institute1302022-12-052025-09-30
Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis
Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray, Mometasone Nasal Irrigation (1 mg capsule), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation - Chronic Rhinitis
Phase 4UnknownEndeavor Health812022-11-232023-07-28
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1572022-07-272023-06-02
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Varenicline Tartrate Nasal Spray, Placebo (vehicle) - Dry Eye Disease
Phase 3CompletedCorxel Pharmaceuticals3402022-07-222023-04-25
Inhaled vs Intranasal Corticosteroids for Chronic Cough in Upper Airway Cough Syndrome
Budesonide (400μg/d), Mometasone Furoate 50mcg Nasal Spray - Chronic Cough (CC), Upper Airway Cough Syndrome
Not applicableCompletedSilesian University of Medicine562022-07-012026-09-16
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Narcan 40 MG/ML Nasal Spray, Naloxone Hydrochloride, Nalmefene HCl injection - Opioid Induced Respiratory Depression, Chronic Opioid Use
Phase 1TerminatedLeiden University Medical Center582022-06-242026-07-29
Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI
56mg esketamine (2x Spravato® 28 mg nasal spray), 0.9% saline solution nasal spray - Ketamine Treatment
Phase 1CompletedRupert Lanzenberger332022-06-012024-04-15
The Role of Nasal Breathing for Perfomance in Elite Athletes.
Oxymetazoline, 0.05% Nasal Spray - Breathing, Mouth
Not applicableCompletedSahlgrenska University Hospital122022-01-132024-07-01
Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2
Nasal Spray - Covid19
Phase 3WithdrawnLarkin Community Hospital2021-12-082023-10-16
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1012021-12-072023-03-23
OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray - Dry Eye
Phase 4CompletedCenter for Ophthalmic and Vision Research, LLC752021-12-032022-11-03
IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray - Dry Eye Disease
Phase 2UnknownVance Thompson Vision - MT202021-12-012021-11-30
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
Nitric Oxide, Nasal spray with isotonic saline - SARS-CoV-2 Infection
Phase 3TerminatedSanotize Research and Development corp.13892021-11-202025-09-25
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
Nitric Oxide - SARS-CoV-2 Infection
Phase 3CompletedSanotize Research and Development corp.3062021-11-012022-10-31

Showing 20 of 60. Sign in to see all of them.

Conditions studied

Dry Eye Syndromes (12)  ·  COVID-19 (7)  ·  Rhinitis, Allergic, Seasonal (7)  ·  Rhinitis, Allergic, Perennial (4)  ·  Migraine Disorders (3)  ·  Rhinitis, Allergic (3)  ·  Coronavirus Infections (2)  ·  Osteoporosis (2)  ·  Rhinitis (2)  ·  Signs and Symptoms (2)  ·  Bone Diseases, Metabolic (1)  ·  Chronic Cough (1)  ·  Crowding (1)  ·  Epilepsy (1)  ·  Headache (1)

Sponsors

Oyster Point Pharma, Inc. (9)  ·  Alcon Research (3)  ·  Dr. Ferrer BioPharma (3)  ·  Archimedes Development Ltd (2)  ·  Corxel Pharmaceuticals (2)  ·  GlaxoSmithKline (2)  ·  Sanotize Research and Development corp. (2)  ·  Sumitomo Pharma America, Inc. (2)  ·  Tarsa Therapeutics, Inc. (2)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (2)  ·  Acorda Therapeutics (1)  ·  Akita Biosciences, Inc. (1)  ·  Azelon Pharmaceuticals (1)  ·  Brandon Baartman (1)  ·  California Medical Clinic for Headache (1)

Countries

United States (31)  ·  China (4)  ·  United Kingdom (3)  ·  Canada (2)  ·  Honduras (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  Dominican Republic (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  India (1)  ·  Jordan (1)  ·  Mexico (1)

Top investigators

Keith Moore, PHARMD (2)  ·  Thomas Legg, D.O. (2)  ·  Alain Serrie, MD (1)  ·  Brandon Baartman, MD (1)  ·  Brian MacDonald (1)  ·  Cort A Pedersen, M.D. (1)  ·  David B Kudrow, MD (1)  ·  David Squillacote, MD (1)  ·  Don Kellerman, PharmD (1)  ·  Gustavo Ferrer, MD (1)

Results publications

PMID 37096956, PMID 36401081, PMID 19490626, PMID 24125150, PMID 24717794, PMID 25028522, PMID 29878341, PMID 30877622, PMID 34456060, PMID 34767866, PMID 34920097, PMID 35472193, PMID 35653029, PMID 35965109, PMID 36107843, PMID 36728653, PMID 37335995, PMID 40088395, PMID 40356464, PMID 41222549, PMID 41557344, PMID 41642634, PMID 41693798, PMID 42180735

NIH funding

2023 (1)